ArticlePLOS global public health2026
Malaria incidence rose following the introduction of neonicotinoid-based IRS in selected districts in northern Ghana: An observational analysis.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative genomics of nicotinic acetylcholine receptors reveals early divergence of the α6 subunit in cryptic Anopheles species.BMC genomics · 2026Article
- Can dual active ingredient Interceptor® G2 insecticide-treated net (ITN) replace indoor residual spraying (IRS) efficiently? A case study in Sakassou, Côte d'Ivoire.Parasites & vectors · 2026Article
- Entomological impact of three years of clothianidin-based indoor residual spraying in two high malaria endemic districts in Côte d'Ivoire.Malaria journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Ghana, indoor residual spraying (IRS) has been a key intervention for malaria control since 2008. After seven years of IRS with an organophosphate insecticide, which substantially reduced malaria incidence, IRS programs transitioned to neonicotinoid-based products between 2018 and 2019 as part of an insecticide rotation plan. This change was largely informed by entomological data from a limited number of pilot districts, with little evidence of epidemiological impact. We assessed the effect of this transition using monthly, district-level malaria incidence from 2015 to 2022 in 22 IRS districts across four northern regions. Incidence was calculated from routinely reported confirmed malaria cases in the Ghana Health Service District Health Information Management System, adjusted for testing rates, with population denominators from census-based estimates. An interrupted time series model with generalized estimating equations was fit to 2015-2019 data, when organophosphates were in use, to generate counterfactual trends through 2022, adjusting for rainfall, temperature, vegetation index, seasonality, and initiation of seasonal malaria chemoprevention. Observed incidence exceeded counterfactual estimates in the first transmission season after the switch and remained higher in subsequent campaigns. Across all districts, malaria incidence was 26% higher under neonicotinoid IRS than expected under continued organophosphate use (IRR = 1.26, 95% CI 1.07-2.08). Regional differences were observed, with significant increases in the Northern (IRR = 1.76, 95% CI 1.04-2.74), North East (IRR = 1.83, 95% CI 1.08-3.40), and Upper East (IRR = 4.26, 95% CI 2.17-8.50) regions, but not in the Upper West (IRR = 1.25, 95% CI 0.90-1.70). These findings suggest that the transition to neonicotinoids may have reduced IRS effectiveness in northern Ghana. Future pilots of new IRS products should incorporate both entomological and epidemiological outcomes to guide region-specific selection before national scale-up.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.